抗雄药物诱导性神经内分泌前列腺癌的研究进展  

Progress of neuroendocrine prostate cancer induced by antiandrogens

作　　者：牛向南 张乐乐 冯安昊 张雁钢 Niu Xiangnan;Zhang Lele;Feng Anhao;Zhang Yangang(Department of Urology,Bethune Hospital Affiliated of Shanxi Medical University,Taiyuan 030032,China;Department of Urology,Shanxi Bethune Hospital,Taiyuan 030032,China)

机构地区：[1]山西医科大学附属白求恩医院泌尿外科,太原030032 [2]山西白求恩医院泌尿外科,太原030032

出　　处：《肿瘤研究与临床》2021年第9期716-720,共5页Cancer Research and Clinic

摘　　要：接受新型雄激素受体途径抑制剂(ARPI)的去势抵抗性前列腺癌(CRPC)的患者往往在治疗应答中表现出耐药性,肿瘤获得雄激素受体(AR)-独立亚型,使癌细胞不再依赖于AR通路继续生长。CRPC患者在接受ARPI治疗后,部分患者不仅未达到临床获益,反而出现疾病进展,即神经内分泌前列腺癌(NEPC),NEPC与不良预后密切相关。迄今为止,临床上鲜见有效且可靠的药物来治疗NEPC。文章旨在总结NEPC的机制和分子靶点,为NEPC患者的诊治方案提供参考。Patients with castration-resistant prostate cancer(CRPC)who received a novel androgen receptor pathway inhibitor(ARPI)often show drug resistance in response to treatment.Tumors acquire androgen receptor(AR)-independent subtypes,so that cancer cells no longer depend on AR pathway to continue to grow.More and more studies have shown that after CRPC patients received ARPI treatment,some patients not only failed to achieve the clinical benefit but also experienced the evolution of tumor progression,that is,neuroendocrine prostate cancer(NEPC).NEPC is closely related to poor prognosis.So far,rare effective and reliable drugs have been found clinically to treat NEPC.This article aims to summarize the mechanism of NEPC and the molecular targets,and provide references for the diagnosis and treatment of NEPC patients.

关 键 词：神经内分泌前列腺癌 内分泌治疗 抗雄药物 诊断 治疗结果 

分 类 号：R737.25[医药卫生—肿瘤]